Peter H. Diamandis

I remember that.

I remember coming to your lab and seeing it.

Full disclosure, I'm also a shareholder, an investor in Ulimit, very proud of that.

So congrats on the progress.

And other news related in epigenetic reprogramming, Life Biosciences, another one of my portfolio companies, announced they've dosed their first patient with their OSK treatment today.

So...

yes we're on the verge of uh longevity escape velocity brian what do you what do you hold as a target for you know when do we hit lev do you have a number in your head do you have a goal you know man we need kurzweil to come plot another curve for us he's got his prediction his prediction is 2033. huh

Well, we're gonna have some level of proof, right?

We have this $101 million healthspan prize going on where we're measuring functional reversal of age, right?

Again, the biomarkers right now, you can test your biomarkers on a Horvath clock and many different clocks.

The problem is if you test yourself in the morning and test yourself at night, you'll get different answers.

And so I don't think there's a reliable biomarker for aging.

Brian, I don't know if you agree with that or not, but what I care about is less a number on a page, but more functional.

Do you have the ability to process liver function that you did earlier in life?

Do you have the cognition, the immune, the muscle that you had 20 years younger?

So I think we're at the beginning of that curve.

And just like in the singularity, we're living through it.

I think we're in the process.

And I agree, GLP-1 drugs are probably one of the very first longevity drugs out there.

Brian, any thoughts?